The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5790-5797

  Tokarski, John S ^a   Newitt, John A ^a   Chang, Chieh Ying J ^a   Cheng, Janet D ^a   Wittekind, Michael ^a   Kiefer, Susan E ^a   Kish, Kevin ^a   Lee, Francis Y F ^a   Borzillerri, Robert ^a   Lombardo, Louis J ^a   Xie, Dianlin ^a   Zhang, Yaqun ^a   Klei, Herbert E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DASATINIB; IMATINIB; MUTANT PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MODELS, MOLECULAR; PIPERAZINES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 33745283618     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4187     Document Type: Article

References (44)

1. Sawyers CL. Chronic myeloid leukemia. N Eng J Med 1999;340:1330-40.
2. Daley GQ, Van Etten KA, Baltimore D. Induction of chronic myelogenous leukaemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
3. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblaslic leukemia. Lenk Lymphoma 2000;36:263-73.
4. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2003;132-52.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Eng J Med 2001;344:1038-42.
7. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
8. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
9. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to ST1-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
10. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8.
11. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
12. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-43.
13. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
14. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methylphenyl)-2-(6-(4-(2-hydroxyethyl) piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-54825). a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
15. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;5:4500-5.
16. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
17. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
18. Sawyers CL, Kantarjian HM, Shah NP, et al. Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase I study [abstract 38]. Blood 2005;106:16a.
19. Guilhot F, Apperley JF, Shah NP, et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: first results of the CA180005 'START-A' study [abstract 39], Blood 2005;106:16a.
20. Talpaz M, Rousselot P, Kim DW, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in myeloid blast crisis who are resistant or intolerant to imatinib: first results of the CA180006 'START-B' study [abstract 40]. Blood 2005;106:16a.
21. Hochhaus A, Baccarani M, Sawyers C, et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 'START-C' phase II study [abstract 41]. Blood 2005;106:17a.
22. Ottmann OG, Martinelli G, Dombret H, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: the 'START-L' CA180015 study [abstract 42]. Blood 2005;106:173.
23. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
24. Weber W, Weber E, Geisse S, Memmert K. Optimisation of protein expression and establishment of the Wave Bioreactor for baculovirus/insect cell culture. Cytotechnoiogy 2002;38:77-85.
25. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-26.
26. French S, Wilson K. On the treatment of negative intensity observations. Acta Crystallogr A 1978;34:517-25.
27. Bailey S. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50 Pt 5:760-3.
28. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr A 1994;50:157-63.
29. Brünger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54 Pt 5:905-21.
30. Nagar B, Hantschel O, Young MA. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112:859-71.
31. Berman HM, Westbrook J, Feng Z. The Protein Data Bank. Nucleic Acids Res 2000;28:235-42.
32. Kim KS, Kimball SD, Misra RN, et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002;45:3905-27.
33. Pierce AC, Sandretto KL, Bemis GW. Kinase inhibitors and the case for CHO hydrogen bonds in protein-ligand binding. Proteins 2002;49:567-76.
34. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996;384:484-9.
35. Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell 1996;85:149-58.
36. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-83.
37. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases: controlling activity through activation segment conformation. Mol Cell 2004;15:661-75.
38. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-63.
39. Heinrich M, Griffith D, Druker B, Wait C, Ott K, Zigler A. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
40. Corless C, Fletcher J, Heinrich M. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
41. Ma Y, Zeng S, Metcalfe D. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
42. Frost M, Ferrao P, Hughes T, Ashman L. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24.
43. Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004;23:139-52.
44. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.